{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:35:57Z","timestamp":1791329757671,"version":"4.3.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.beha.2010.01.006","type":"journal-article","created":{"date-parts":[[2010,6,24]],"date-time":"2010-06-24T09:10:54Z","timestamp":1277370654000},"page":"133-143","source":"Crossref","is-referenced-by-count":17,"title":["Monoclonal antibody therapy of chronic lymphocytic leukaemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2010.01.006_bib1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1098\/rspl.1899.0121","article-title":"On immunity with special reference to the cell of life","volume":"66","author":"Ehrlich","year":"1900","journal-title":"Proc Royal Soc London"},{"key":"10.1016\/j.beha.2010.01.006_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.beha.2010.01.006_bib5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin","volume":"67","author":"Nadler","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2010.01.006_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.1984.2.8.881","article-title":"Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody","volume":"2","author":"Dillman","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib7","first-page":"394","article-title":"Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma","volume":"5","author":"Dillman","year":"1986","journal-title":"J Biol Response Mod"},{"key":"10.1016\/j.beha.2010.01.006_bib8","first-page":"97","article-title":"A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia","volume":"7","author":"Hertler","year":"1988","journal-title":"J Biol Response Mod"},{"key":"10.1016\/j.beha.2010.01.006_bib9","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood.V67.6.1680.1680","article-title":"Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients","volume":"67","author":"Laurent","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib10","first-page":"112","article-title":"Treatment of chronic lymphocytic leukaemia with monoclonal anti-idiotype antibody","volume":"28","author":"Capel","year":"1985","journal-title":"Neth J Med"},{"key":"10.1016\/j.beha.2010.01.006_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","article-title":"The CAMPATH-1 antigen (CDw52)","volume":"35","author":"Hale","year":"1990","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.beha.2010.01.006_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2010.01.006_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood.V73.6.1431.1431","article-title":"Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype","volume":"73","author":"Dyer","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib14","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia","volume":"15","author":"\u00d6sterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib15","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib16","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib18","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2010.01.006_bib19","first-page":"676","article-title":"Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901","volume":"102","author":"Rai","year":"2003","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2010.01.006_bib20","first-page":"205a","article-title":"A phase II trial of fludarabine followed by alemtuzumab (CAMPATH-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901","volume":"100","author":"Rai","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib21","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","article-title":"CAMPATH-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia","volume":"99","author":"Kennedy","year":"2002","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2010.01.006_bib22","first-page":"690a","article-title":"FluCam - a new, 4-weekly combination of fludarabine and alemtuzumab for patients with relapsed chronic lymphocytic leukemia","volume":"104","author":"Elter","year":"2004","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.V114.22.224.224","volume":"114","author":"Engert","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib24","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.V114.22.3431.3431","article-title":"Chemoimmunotherapy with cyclophosphamide, fludarabine, alemtuzumab and rituxiamb (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL)","volume":"114","author":"Badoux","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib25","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.leu.2403190","article-title":"Successful CD34+ cell mobilization by intermediate-dose ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and CAMPATH-1H","volume":"18","author":"Montillo","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2010.01.006_bib27","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual diseasee after chemotherapy on patients with chronic lymphocytic leukemia","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood.V114.22.92.92","volume":"114","author":"Lin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2141.2008.07394.x","article-title":"Consolidation with alenmtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first clinical remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)","volume":"144","author":"Schweighofer","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2010.01.006_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2010.01.006_bib31","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib33","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (Chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib35","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib36","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","article-title":"Rituximab treatment of refractory fludarabine -associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"100","author":"Hegde","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib37","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib38","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood.V114.22.539.539","article-title":"Treatment with fludarabine and rituximab produces extended overall survival (OS) and progession-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of secondary malignancy: long-term follow-up of CALGB study 9712","volume":"114","author":"Woyach","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib41","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib43","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood.V114.22.535.535","volume":"114","author":"Hallek","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib45","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/blood.V114.22.538.538","volume":"114","author":"Lepretre","year":"2009","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2010.01.006_bib47","first-page":"365a","article-title":"Phase I study of rituximab and CAMPATH-1H in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"98","author":"Nabhan","year":"2001","journal-title":"Blood"},{"issue":"part 1","key":"10.1016\/j.beha.2010.01.006_bib48","first-page":"800a","article-title":"The combination of alemtuzumab continuous intravenous infusion (civ) followed by subcutaneous injection (sc) plus rituximab has activity in patients (pts) with relapsed chronic lyhmphocytic leukemia (CLL)","volume":"108","author":"Faderl","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib49","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib50","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib52","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2010.01.006_bib53","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1\u20132 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2010.01.006_bib54","first-page":"373","article-title":"High activity of single-agent ofatumumab, a novel CD20 monoclonal antibody, in fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia","volume":"94","author":"Wierda","year":"2009","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib55","first-page":"364","article-title":"Phase I study of RO5072759 (GA101) in relapsed\/refractory chronic lymphocytic leukemia","volume":"114","author":"Morchhauser","year":"2009","journal-title":"Blood"},{"issue":"15 Pt 1","key":"10.1016\/j.beha.2010.01.006_bib56","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","article-title":"Phase I study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Byrd","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 4","key":"10.1016\/j.beha.2010.01.006_bib57","article-title":"Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I\/II multicenter study","volume":"19","author":"Byrd","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2010.01.006_bib58","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"issue":"15s","key":"10.1016\/j.beha.2010.01.006_bib59","first-page":"451s","article-title":"Evaluation of the effect of TRU-16, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma","volume":"27","author":"Baum","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2010.01.006_bib60","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.V114.22.3424.3424","article-title":"A phase 1 trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP\u2122) proteein in relapsed and refractory CLL: early promising clinical activity","volume":"114","author":"Andritsos","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2010.01.006_bib61","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692610000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692610000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T03:06:54Z","timestamp":1591412814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692610000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1521692610000071"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2010.01.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}